Alladapt Immunotherapeutics Inc., a private biopharmaceutical company focused on the development of prescription therapeutics to address food allergy, today announced the completion of a $60 million Series C financing. The round was led by Gurnet Point Capital, a private investment fund, which has been involved with Alladapt since the Company’s founding in 2018. Proceeds from … [Read more...] about Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy Therapeutics